Posted on: October 13, 2018
Dr. Kosiborod will discuss the fundamental paradigm shift in T2D management. He will review several classes of glucose-lowering medications that improve CV outcomes and emerging data on the shift of focus from HbA1c alone to comprehensive CV risk reduction. Finally, he will share why all of this points to the need for cardiologists to take a more active role in T2D management.
Unlock the full article by signing up for a MedAxiom Membership